Nautilus Biotechnology, Inc.
NAUT · XNASCIK 1808805fmd_1C4ETCPZRGGYV53CZ7Y5BGBP9PManufacturing · Laboratory Analytical InstrumentsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 26 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Research and development | 12 | 29 | 38 | 47 | 50 | 41 |
| Total operating expenses | 16 | 50 | 64 | 76 | 81 | 67 |
| Other non-operating income (expense) | 0 | 0 | 6 | 12 | 11 | 8 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (16) | (50) | (58) | (64) | (71) | (59) |
| Net income to common shareholders | (16) | (50) | (58) | (64) | (71) | (59) |